Kornimate/medical-research-clean huggingface dataset:
efficacy of acute lymphoblastic leukemia-based therapy in treating patients with acute leukemia of ambiguous lineage

Conditions: Acute Leukemia of Ambiguous Lineage

Summary: in this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. patients will receive acute lymphoblastic leukemia (all) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (hsct) after cr . otherwise, they will finish the consolidation chemotherapy. patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. the purpose of current study is to evaluate the clinical efficacy of all-based chemotherapy，effect of genetic abnormality and minimal residual disease (mrd) on prognosis in patients with acute leukemia of ambiguous lineage.


Eligibility criteria:
inclusion criteria: 1. patients aged above 14 years with acute leukemia of ambiguous lineage . 2. eastern cooperative oncology group (ecog) performance status 2. 3. adequate end organ function as defined by: total bilirubin ≤ 1.5 x upper limit of normal (uln); serum glutamic-oxaloacetic transaminase(sgot) and serum glutamic pyruvic transaminase(sgpt) ≤ 2.5 x uln; creatinine ≤ 1.5 x uln; serum amylase and lipase ≤ 1.5 x uln; alkaline phosphatase ≤ 2.5 x uln unless considered tumor related; patients must have adequate cardiac function (ejection fraction ≥ 45 % on multiple gated acquisition (muga) scan). 4. patients must have the following laboratory values (≥ lower limit of normal (lln) or corrected to within normal limits with supplements prior to the first dose of study medication.): potassium ≥ lln; magnesium ≥ lln; phosphorus ≥ lln 5. patients should sign informed consent form. exclusion criteria: 1. impaired cardiac function: long qt syndrome or a known family history of long qt syndrome; clinically significant resting brachycardia (\ 450 msec on baseline ecg (using the qtcf formula). if qtcf interval\>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for qtc. myocardial infarction within 12 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias). 2. other concurrent severe and/or uncontrolled medical conditions: patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease. 3. patients who are: (a) pregnant and (b) breast feeding.
implementation and evaluation of an electronic alert to encourage targeted screening for hiv infection at foch hospital according to socio-demographic criteria

Conditions: HIV Testing

Summary: in 2013 in france, 29,000 people are reported to be unaware of their hiv status. hiv testing is a priority in france where one third of all diagnoses remain late despite 5 million annual tests. it is recommended to offer at least one hiv test to the general population, over the life course, when seeking care and more frequently to populations at risk. several international and national articles have shown that emergency screening is feasible and well accepted. but also that during systematic screening few infections were discovered, and the majority of newly diagnosed people belonged to the most exposed groups. our hypothesis is that an electronic alert would identify people who are unaware of their hiv status. this alert would be based on two data: social data (french health coverage) and the country of birth. this alert is only relevant in high-prevalence regions, as is the case in the ile de france region.


Eligibility criteria:
inclusion criteria: * patient hospitalized at foch hospital over 18 years of age. * patient with ame or cmu and/or cmuc, or patient born in one of the following countries/regions: sub-saharan africa, haiti, south america, asia, eastern europe, guadeloupe, martinique and guyana exclusion criteria: * patient whose vital prognosis at the time of admission does not allow him/her to indicate his/her non-opposition to an hiv test. * patient being followed for a known hiv infection.

Keywords: medical practices hiv electronic alert
chronic pain after cs in egypt

Conditions: Chronic Pain

Summary: this retrospective study will include women who will attending to azhar assuit, sohag and south valley universities hospitals for any reason in the duration from 1 may to 31 october 2021, and who underwent elective cd under spinal anesthesia with horizontal lower abdominal surgical incision within last two years. exclusion criteria will be refusal to participate, age less than 18 years, recent cd (within 3 months), if the infant had died, and history of chronic pain medications or psychiatric disorder. data collection participants will be contacted personally by one of study authors. data collected are consisted of: * participants' characteristics as age, parity and ways of delivery, weight, height, residency, husband smoking status, work, previous abdominal surgery, history of diabetes mellitus and hypertension. * last cd related data which include presence of multiple pregnancies, if cd was in private/public facility, presence surgical wound infection. * pain experienced will be assessed by questionnaire described by nikolajsen et al, 2004


Eligibility criteria:
inclusion criteria: * women attending to azhar assuit, sohag and south valley universities hospitals for any reason in the duration from 1 may to 31 october 2021, and who underwent elective ceserean section under spinal anesthesia with horizontal lower abdominal surgical incision within last two years exclusion criteria: * refusal to participate, age less than 18 years, recent ceserean section (within 3 months), if the infant had died, and history of chronic pain medications or psychiatric disorder
intraperitoneal mesh-implementation after laparotomy

Conditions: Incisional Hernia

Summary: aim of the study is to evaluate the risk reduction of intraperitoneal mesh-implementation after laparotomy (group 1) in a randomized control trial compared with patients with standard abdominal closure (everett-suture). this is the primary endpoint. second endpoints are the feasibility of mesh-implementation even after colorectal surgery, find risk factors for wound infection and incisional hernia.


Eligibility criteria:
inclusion criteria: * informed consent * median laparotomy exclusion criteria: * bowel perforation * pregnancy * palliative surgery * drug abuse * age under 18 * mental disability * allergy to mesh components
comparative analysis of nemonoxacin and other anti-methicillin resistant staphylococcus aureus (anti-mrsa) antimicrobial therapy in patients with complicated skin and soft tissue infections (cssti): a retrospective chart review study

Conditions: Methicillin-susceptible S. Aureus (MSSA); Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA); Complicated Skin and Soft Tissue,cSSTI

Summary: increasing rates of antimicrobial resistant bacterial infections and antimicrobial therapy at home in elderly are great concern for medical care. the availability of new antibacterial agents that are effective against bacteria with resistance to other antibacterials is therefore critical to continued successful management of bacterial illnesses in the future. nemonoxacin is a c-8 methoxy, non-fluorinated quinolone that retains potent broad-spectrum activities against gram-positive and gram-negative bacteria by selective inhibition of bacterial dna topoisomerase. nemonoxacin had greater in-vitro activity against many gram-positive bacteria, including methicillin-susceptible s. aureus (mssa), and ciprofloxacin-susceptible and ciprofloxacin-resistant mrsa, levofloxacin-susceptible and levofloxacin-resistant s. pneumoniae, streptococcus pyogenes, streptococcus agalactiae, enterococci, and enterobacterieacea species except pseudomonas aeruginosa. lowe selected mutation of nemonoxacin, compared with other fluoroquinolones against antimicrobial resistant gram-positive bacteria had been reported.\[5\] nemonoxacin could be used once-daily oral and intravenous formulations for the treatment of community-acquired pneumonia, including methicillin resistant staphylococcus aureus (mrsa). however, nemonoxacin has less evidence of efficacy for complicated skin and soft tissue infection. in this retrospective study, we will investigate the treatment outcomes of nemonoxacin and compared with other anti-methicillin resistant staphylococcus aureus (anti-mrsa) antimicrobial therapy in patients with complicated skin and soft tissue infections (cssti) by chart review.


Eligibility criteria:
inclusion criteria: * complicated skin and soft tissue (cssti) infection exclusion criteria: * no complicated skin and soft tissue (cssti) infection

Keywords: methicillin-susceptible s. aureus (mssa) nemonoxacin anti-methicillin resistant staphylococcus aureus (anti-mrsa) complicated skin and soft tissue,cssti
children, adolescents and young adults with myeloproliferative neoplasia: study of clinico-biological characteristics and complications (vyp)

Conditions: Myeloproliferative Neoplasm

Summary: the creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. it will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.


Eligibility criteria:
inclusion criteria: * patient diagnosed with non-lmc mpn before the age of 30 (pv or te or mfp or premf) according to the 2016 who criteria. * signature of the consent form for participation in the fimbank project. * agreement to participate in the vyp study. * patient of legal age at the time of inclusion in vyp. * patient affiliated to a social security scheme exclusion criteria: * refusal to participate by patients of full age * patient under legal protection (guardianship, curatorship, etc.)
a study to estimate the time course of pf-00241939 concentration in the blood following dosing by oral inhalation from dry powder inhalers.

Conditions: Healthy

Summary: the purpose of this study is to investigate the time course of pf-00241939 concentration in the blood following dosing by oral inhalation from dry powder inhalers.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 21 and 55 years. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * a positive urine drug screen. * history of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males. * pregnant or nursing females.

Keywords: pharmacokinetics
diagnostic and evaluation of hepato-pancreatico-biliary disease with mri

Conditions: Liver Diseases; Pancreas Disease

Summary: this is a retrospective review of images from patient data. there is no recruitment necessary for this study. research question: can advanced multiparametric mri techniques improve the detection and characterization of focal and diffuse liver disease, accurately assess treatment response and predict patient outcomes based on longitudinal monitoring? hypotheses: advanced multiparametric mri techniques improve the detection, characterization and response assessment of focal and diffuse liver disease and can predict serious liver related outcomes.


Eligibility criteria:
inclusion criteria: * patients with suspicion for or diagnosed focal and/or diffuse liver or pancreatic disease who underwent mri of the abdomen. * 18 years of age and older. exclusion criteria: * age less than 18 years. * lack of mri of the abdomen. * inadequate image quality. * documented rejection to participate in research studies
prenatal cocaine, nasal oxytocin, and maternal psychophysiology

Conditions: Substance Abuse Problem; Pregnancy

Summary: the purpose of this research is to study the effects of nasal oxytocin administration on maternal behaviors that may be influenced by cocaine use during pregnancy. 32 mothers with prenatal use of cocaine during the current pregnancy will be studied at 3-6 months postpartum, when they will complete 3 study visits, a 2-week double-blind trial of twice daily nasal spray (oxytocin or placebo) and 4 telephone interviews. all information collected is confidential.

participation for mothers when they are 3-6 months postpartum includes: * visit 1: questionnaires and interviews about participants' health, pregnancy, moods, psychological history and drug use during pregnancy and postpartum. * visit 2: pregnancy \& drug tests (results are confidential), blood samples and vital signs, video-taped mother-infant interaction, speech task, instruction re: using nasal spray (oxytocin or placebo) \& self-administration of first nasal spray dose, followed by 90 minutes of monitoring. * at-home nasal spray: twice daily (before breakfast and supper) nasal spray self-administration for 14 days. * visit 3: pregnancy \& drug tests (results are confidential), blood samples and vital signs, video-taped mother-infant interaction, speech task, interviews and questionnaires about mothers' experience with the nasal spray, and changes in mood or physical discomfort during the 2-weeks when taking the nasal spray. * 3 telephone interviews while subjects are taking nasal spray, and 1 post-trail telephone follow-up.

Eligibility criteria:
inclusion criteria: * 3-6 months postpartum at start of testing * cocaine use during current pregnancy (by self-report or medical record of prenatal urine toxicology) * exclusive formula-feeding for all infant milk feedings (no infant feeds will be breast milk) * healthy singleton pregnancy * english fluency that will allow informed consent exclusion criteria: * pregnancy or plans to become pregnant during participation in the study * not using effective birth control methods to prevent pregnancy * breastfeeding for any infant milk feedings * mother is not currently living with the infant during the trial period * multiple birth (twin, triplet or greater)

Keywords: cocaine mothers pregnant women postpartum women oxytocin substance use disorders substance abuse prenatal substance use stress
triple therapy in real-life: impact on adherence and health status (tritrial)

Conditions: COPD

Summary: the mean objectives are to evaluate the impact of bdp/ff/g fixed combination on health-status and adherence


Eligibility criteria:
inclusion criteria: 1. written informed consent to participate in the study; 2. adult patients of either sex aged ≥ 40 years; 3. patients with diagnosis of moderate to very severe copd according to gold initiative for chronic obstructive lung disease (gold) updated 2019 (gold stage 2-4); 4. copd assessment test (cat) score ≥ 10 at initiation of bdp/ff/g fixed combination; 5. history of \>1 moderate or severe copd exacerbation during the previous year. 6. patients in treatment with bdp/ff/g as per local clinical practice and according to trimbow® summary of product characteristics (smpc). exclusion criteria: 1. according on investigator's judgement, patients unable to comply with the requirements of the study (e.g. inability to attend all the planned study visits according to the time limits included) or patients with poorly controlled concomitant severe diseases or conditions that could interfere with the study participation; 2. participation in an interventional clinical trial within 30 days prior to enrolment into the present study.

Keywords: copd adherence hrqol determinants
cardiorespiratory fitness, apolipoprotein e genotype, and cognitive functions: a prospective study

Conditions: Aging; Cognitive Change

Summary: the current research project aims to investigate the interaction of cardiorespiratory fitness (crf) and the apoe genotype with neurocognitive functions.

the current research project aims to investigate the interaction of cardiorespiratory fitness (crf) and the apoe genotype with neurocognitive functions. the three main purposes of the current research project seek to achieve: 1. an exploration of the associations of, as well as the interactions between, crf assessed at the baseline stage, and the apoe genotype, along with cognitive functions in cognitively healthy late-middle-aged older adults. 2. the employing of an event-related potential (erp) to investigate the associations between the baseline crf, the apoe genotype, and cognitive functions in cognitively healthy late-middle-aged older adults, as well as the potential underlying neuroelectrical mechanisms. 3. an investigation of the interactions between the changes of crfs assessed at the baseline and the follow-up stages and the apoe genotype in relation to neurocognitive function, as well as the underlying neuroelectrical mechanisms, in cognitively healthy late-middle-aged older adults.

Eligibility criteria:
inclusion criteria: * right handed * no history of cardiorespiratory disease * normal or corrected-to-normal vision based on the 20/20 standard * no risk of performing physical activities, as measured by the physical activity readiness questionnaire exclusion criteria: * the scores of mini-mental status examination (mmse) \< 25 and cognitively intact upon study entry * history of psychiatric or neurological diseases * color-blindness

Keywords: physical fitness apolipoprotein e event-related potential
cardiotoxicity in breast cancer patients treated with proton or photon radiotherapy: a radcomp companion study

Conditions: Breast Cancer; Cardiotoxicity

Summary: this is a companion study to the "pragmatic randomized trial of proton vs photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: a radiotherapy comparative effectiveness (radcomp) consortium trial" (nct02603341). the investigators will collect cardiovascular (cv) biomarkers and echocardiograms prior to, during, and for up to 1 year following radiation for a subset of patients enrolled on radcomp and to evaluate the impact of proton vs photon radiation therapy (rt) on cv function and structure.

the study population of the companion study will consist of newly enrolled radcomp trial participants. patients on this ancillary will be consented prior to radcomp randomization to decrease the bias secondary to rt type and enhance internal validity. the study will define the early changes in biomarkers, imaging measures, and rt dose volume metrics and long-term (5-10 year) cv clinical outcomes using the radcomp parent study's infrastructure for clinical data collection and long-term follow-up. blood samples, echocardiograms, and questionnaires are obtained at baseline (between end of chemotherapy and start of rt), immediately after the end of rt, and at 6 months and 12 months after the end of rt. an additional blood sample will be collected at 4 weeks after the start of rt. clinical, demographic, and patient reported outcomes data are collected as part of the radcomp parent study. in addition to data collected by radcomp, we will collect a limited set of clinical data and two additional quality of life instruments for the companion study.

Eligibility criteria:
inclusion criteria: * consented to radcomp * willing and able to provide written consent exclusion criteria: * knowledge of randomization on radcomp prior to enrollment on companion study * non-diagnostic echocardiography windows as assessed on local read.

Keywords: cardio-oncology radiation therapy cardiotoxicity
anemia of inflammation and deficiency anemia

Conditions: Anemia, Iron Deficiency; Anemia of Chronic Disease

Summary: critical patients which requiring admission to intensive care (it) are a special group of patients. in these patients the prevalence of anemia reported in studies is 75%. this prevalence is similar to that in the retrospective observational study conducted in our intensive care unit(icu). of the 783 patients included in the study, 551 (73.37%) had anemia on admission. frequently anemia is present on discharge from icu or hospital and may persist for an average of 11 weeks. some studies have reported the presence of anemia as far as 6 months after discharge. it is widely accepted that anemia has a negative impact on rehabilitation and quality of life, but the treatment can not be exclusively based on blood products due to the risks associated with transfusion. alternative treatments such as injectable iron or erythropoietin should be considered. the transfusion management initiative group recently issued recommendations on perioperative anemia. similar recommendations for icu have not yet been developed in romania. the current study has two main purposes. the first to adopt the perioperative anemia diagnostic algorithm and adapt it to anemic patients on icu; the second to identify patients with mixed anemia (inflammatory and iron deficient anemia) who can benefit from treatment with iron.


Eligibility criteria:
inclusion criteria: patients admitted to icu icu stay \>48hours exclusion criteria: * refusal to participate in the study * allergy to iron products * anemia requiring massive transfusion in the last 7 days * treatment of iron products in the last 7 days * chronic renal failure with gfr \<30ml / min or on dialysis * metabolism of iron * pregnant or lactation patients * rheumatic diseases * inflammatory bowel diseases * hematological pathologies * impossibility of performing laboratory tests within 72 hours of admission
terbinafine compared to griseofulvin in children with tinea capitis

Conditions: Tinea Capitis

Summary: tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. the infection is caused by a relatively small group of dermatophytes in the genera trichophyton and microsporum. terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. this study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.


Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of tinea capitis confirmed by positive koh determined by the central mycology laboratory. * male or female patients who are at least 4 years old and no more than 12 years old. exclusion criteria: * patients having a medical condition that alters the absorption and/or metabolism of terbinafine (e.g. liver, renal disease etc.) * patients receiving medication that may interfere with the evaluation of the drug's effect * patients who have kerions requiring immediate treatment or treatment with systemic corticosteroids and/or systemic antibiotics * patients with a history of liver disease or current/active liver disease or with elevation of livery enzymes outside of the normal range corresponding to their age * patients who have received recent systemic or topical treatment for tinea capitis within the specified time periods (e.g. systemic antifungals within 2 months of screening visit, topical treatments \[e.g. antifungals, corticosteroid preparations, zinc pyrithione or selenium sulfide or tar containing products\] within 1 week of screening). * patients with a history of systemic lupus erythematosus

Keywords: terbinafine, tinea capitis, pediatric, antifungal